Pharmacokinetic study of fibrin clot-ciprofloxacin complex: an in vitro and in vivo experimental investigation

Tsourvakas, Stefanos; Hatzigrigoris, P.; Tsibinos, A.; Kanellakopoulou, K.; Giamarellou, Helen; Dounis, Eleftherios

doi:10.1007/bf00452091

Cited by 33 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Transforming Growth Factor β1 [10,11] Platelet-Derived Growth Factors (PDGF-BB, AB) [12,13] Insuline Like Growth Factor (IGF-1) [12] Interleukin-1β [14] Epidermal Growth Factor (EGF) [15] Enzymes/proenzymes Plasminogen [16] Tissue Plasminogen Activator (tPA) [16] Plasminogen Activator Inhibitor [17] Thrombin [18] Neomycin, Gentamicin, Polymyxin E in vitro [81] Cephalotin in vitro and in vivo [82] Cefotaxime in vivo [83] Metranidazole, Bacitracine in vivo [84] Cefoxitin, Gentamicin in vivo [85] Tobramycin in vitro and in vivo [86] Gentamicin derivative in vitro and in vivo [87] Ceftazydime,Tobramycin, Gentamicin,Clindamycin, Ampicillin in vitro [88] Teicoplanin,Ciproflaxacin, Cefoxitin, Gentamicin in vitro [89] Gentamycin derivative in vitro and in vivo [90] Clindamycin, Cefotaxime in vivo [91] Sisomicin in vivo [92] Neomycine in vivo [93] Cifroflaxacin in vitro and in vivo [94] Ampicillin, Debakacin, Gentamicin, Carbenicillin, Ceftazidin, Cefoxitin, Cefoxitin, Polymixin B, Mupirocin, Norflaxacin,Clindamycin,Nitrofurazone in vitro [95] Oflaxacin, Ampicillin, Gentamicin in vitro [96] Abrekacin sulfate in vitro and in vivo [97] Vancomycin, Cephalothin, Gentamicin, Teicoplanin in vitro and in vivo [98] Tetracyclin in vivo [58] Tetracyclin in vitro and in vivo [31] Tetracyclin in vitro [36] Ceftazidime, Moxifloxacin, Lomefloxacin,Vancomycin in vivo [99] Vancomycin in vivo [100] …”

Section: Page 25 Of 51mentioning

confidence: 99%

Fibrin matrices: The versatile therapeutic delivery systems

Ahmad

Fatima

Hoque

et al. 2015

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Section: Page 25 Of 51mentioning

confidence: 99%

Fibrin matrices: The versatile therapeutic delivery systems

Ahmad

Fatima

Hoque

et al. 2015

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

“…Nonbiodegradable drug delivery systems are typically PMMA bone cements or beads. Biodegradable forms of drug‐delivery systems are more varied, and include the following: collagen sponges soaked with an antibiotic,20, 21 apatite‐wollastonite glass ceramic,22, 23 hydroxyapatite,24–27 β‐tricalcium phosphate (β‐TCP) [Ca 3 (PO 4 ) 2 ],28–31 polylactide/polyglycolide implants,32 fibrin clots,33 and polyurethanes 34. Hydroxyapatite and β‐TCP have been shown to be appreciably bioactive 35.…”

Section: Introductionmentioning

confidence: 99%

In vitro tobramycin elution analysis from a novel β‐tricalcium phosphate–silicate‐xerogel biodegradable drug‐delivery system

et al. 2004

View full text Add to dashboard Cite

This in vitro research analyzed local tobramycin elution characteristics from a novel, biodegradable drug delivery system, consisting of a beta-TCP bone substitute, VITOSS trade mark, encapsulated with silicate xerogel prepared by the sol-gel process. Tobramycin elution from silicate-xerogel-encapsulated VITOSS was compared directly with non-silicate-xerogel-encapsulated VITOSS to assess whether xerogels are effective in delivering greater tobramycin quantities in a controllable, sustained manner crucial for microbial inhibition. Tobramycin elution characteristics indicate an initial release maximum during the first 24 h that diminishes gradually several days after impregnation. The copious tobramycin quantity eluted from the VITOSS/silicate-xerogel systems is attributed to various factors: the intrinsic ultraporosity and hydrophilicity of VITOSS, the ability of tobramycin to completely dissolve in aqueous media, tobramycin complexation with highly polar SO(4) (2-) salts that further assist dissolution, and ionic exchanges between VITOSS and the environment. Silicate-xerogel-encapsulated VITOSS eluted 60.65 and 61.31% of impregnated tobramycin, whereas non-silicate-xerogel-encapsulated VITOSS eluted approximately one-third less impregnated tobramycin, at 21.53 and 23.60%. These results suggest that silicate xerogel optimizes tobramycin elution because of its apparent biodegradability. This mechanism occurs through xerogel superficial acidic sites undergoing exchanges with various ions present in the leaching buffer. Tobramycin elution kinetics were evaluated, and demonstrate that first-order elution rate constants are considerably less when silicate xerogels are employed, following a more uniform exponential decay-type mechanism, thus bolstering controlled release. Overall, tobramycin elution rates adhere to linear-type Higuchi release profiles. Elution rate constants are initially first order, and taper into zero-order elution kinetics in the latter stages of release. Because VITOSS and silicate xerogel are completely biodegradable, essentially all impregnated tobramycin will be delivered to the surgical site after implantation.

show abstract

“…The release of antibiotics is controlled by the dissolution of the fibrin sealant by fibrinolysis and diffusion through the fibrin matrix. Most experimental studies have revealed a high output of antibiotics within the first several days from the fibrin-antibiotic mixtures, and this relatively short duration of the release of large amounts of antibiotic mainly resulted from rapid diffusion [16][17][18][19]. Local hematomas are well known as an excellent culture media for harboring bacteria.…”

Section: Discussionmentioning

confidence: 99%

The use of antibiotic-impregnated fibrin sealant for the prevention of surgical site infection associated with spinal instrumentation

Tofuku

Koga

Yanase³

et al. 2012

Eur Spine J

View full text Add to dashboard Cite

Purpose The purpose of this study was to determine if the use of antibiotic-impregnated fibrin sealant (AFS) was effective in preventing surgical site infections (SSI) associated with spinal instrumentation. Methods In a preliminary study, five pieces of vancomycin-impregnated fibrin sealant, five nuts that were not treated with the sealant, and five nuts that were treated with the sealant were subjected to agar diffusion testing. In a clinical study, the rates of deep SSI were compared between 188 patients who underwent procedures involving spinal instrumentation without AFS (group 1) and 196 patients who underwent procedures involving spinal instrumentation with AFS (group 2). Results All five pieces of vancomycin-impregnated fibrin sealant and the five nuts treated with the sealant exhibited antimicrobial efficacy, while the five untreated nuts did not exhibit antimicrobial efficacy in the agar diffusion test. In the clinical study, 11 (5.8 %) of the 188 patients in group 1 acquired a deep SSI, while none (0 %) of the 196 patients in group 2 acquired a deep SSI. Conclusion The present study demonstrated that the application of AFS to spinal instrumentation yielded good clinical outcomes in terms of the prevention of postoperative spinal infections. It is hoped that limiting AFS use to patients requiring spinal instrumentation and those with risk factors for SSI will reduce the overall costs while preventing SSIs.

show abstract

Pharmacokinetic study of fibrin clot-ciprofloxacin complex: an in vitro and in vivo experimental investigation

Cited by 33 publications

References 9 publications

Fibrin matrices: The versatile therapeutic delivery systems

Fibrin matrices: The versatile therapeutic delivery systems

In vitro tobramycin elution analysis from a novel β‐tricalcium phosphate–silicate‐xerogel biodegradable drug‐delivery system

The use of antibiotic-impregnated fibrin sealant for the prevention of surgical site infection associated with spinal instrumentation

Contact Info

Product

Resources

About